DIANE DEBLASE: Open Payments
NPI 1598998783 · MARLTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$914 in 43 payments from 11 companies in 2025. Trend: 2023 $770 · 2024 $465 · 2025 $914
Food & beverage: $914
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 9 | $231 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $219 |
| ABBVIE INC. | 9 | $147 |
| Janssen Pharmaceuticals, Inc | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 3 | $55 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Tris Pharma Inc | 1 | $16 |
Products named: CAPLYTA, LYBALVI, VRAYLAR, FANAPT, REXULTI, AUSTEDO XR, SPRAVATO, ARISTADA.
Industry payments across NJ — which companies pay providers there.
